Trials / Conditions / Acquired Thrombotic Thrombocytopenic Purpura

Acquired Thrombotic Thrombocytopenic Purpura

8 registered clinical trials studyying Acquired Thrombotic Thrombocytopenic Purpura — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008	Peking University People's Hospital	Phase 2
Completed	Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura NCT05876221	University of Cologne	—
Active Not Recruiting	Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thromboti NCT05046717	Fundación Española de Hematología y Hemoterapía	—
Recruiting	Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP NCT04985318	University of Cologne	—
Unknown	A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP) NCT04021173	Lee's Pharmaceutical Limited	Phase 2
Completed	Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) NCT02878603	Sanofi	Phase 3
Completed	Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura NCT02553317	Ablynx, a Sanofi company	Phase 3
Completed	Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thr NCT01151423	Ablynx, a Sanofi company	Phase 2